Your browser doesn't support javascript.
loading
Self-Assembled Multilayer Films for Time-Controlled Ocular Drug Delivery.
Machado, Mónica; Silva, Gabriela A; Bitoque, Diogo B; Ferreira, Joana; Pinto, Luís A; Morgado, Jorge; Ferreira, Quirina.
Afiliación
  • Machado M; Instituto de Telecomunicações, Avenida Rovisco Pais, Lisbon 1049-001, Portugal.
  • Silva GA; CEDOC Chronic Diseases Research Centre, NOVA Medical School, Universidade Nova de Lisboa, Campo Mártires da Pátria 130, Lisboa 1169-056, Portugal.
  • Bitoque DB; NOVA Medical School/Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon 1169-056, Portugal.
  • Ferreira J; CEDOC Chronic Diseases Research Centre, NOVA Medical School, Universidade Nova de Lisboa, Campo Mártires da Pátria 130, Lisboa 1169-056, Portugal.
  • Pinto LA; Ophthalmology Department, Centro Hospitalar Universitário de Lisboa Central, Lisbon 1169-050, Portugal.
  • Morgado J; NOVA Medical School/Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon 1169-056, Portugal.
  • Ferreira Q; Ophthalmology Department, Centro Hospitalar Universitário de Lisboa Norte, Lisbon 1649-035, Portugal.
ACS Appl Bio Mater ; 2(10): 4173-4180, 2019 Oct 21.
Article en En | MEDLINE | ID: mdl-35021432
ABSTRACT
The patient's compliance on the therapeutics to treat glaucoma is significantly low contributing for a fast evolution of the disease. This article presents an autonomous system with controlled release using an alpha2-adrenergic receptor agonist, brimonidine, usually used to treat glaucoma. More specifically, biocompatible and layer-by-layer drug delivery films containing monolayers with brimonidine encapsulated in polymer-ß-cyclodextrin were prepared with the objective to obtain a system able to release precise amounts of drug at specific times. To delay the erosion-controlled drug release, we included nanosheets of graphene oxide and layers of a biodegradable polymer (poly-ß-aminoester) between the drug-containing monolayers to obtain a time-controlled drug delivery system. An increase in the number of graphene oxide layers is proportional to the brimonidine release delay and its kinetic release can be tuned as a function of the number of layers. Two types of films with brimonidine encapsulated in ß-cyclodextrin were analyzed. One of them composed of barrier layers with PBAE and another with two types of barrier layers, PBAE and graphene oxide. The results indicate that one graphene oxide bilayer can delay the brimonidine release for more than 24 h. In vitro assays confirmed that the films have a cell viability of 100%.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: ACS Appl Bio Mater Año: 2019 Tipo del documento: Article País de afiliación: Portugal

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: ACS Appl Bio Mater Año: 2019 Tipo del documento: Article País de afiliación: Portugal